Emerald Health Therapeutics Revenue Growth Rates (EMHTF), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Emerald Health Therapeutics Inc.  (EMHTF)
 

EMHTF's Revenue Growth by Quarter and Year

Emerald Health Therapeutics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EMHTF Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
4th Quarter December 3.72
3rd Quarter September 7.36
2nd Quarter June 3.79
1st Quarter March 1.96
FY 16.83





EMHTF Revenue fourth quarter 2018 Y/Y Growth Comment
Emerald Health Therapeutics Inc. reported Revenue surge of 327.7% year on year in the fourth quarter 2018, to $ 3.72 millions, this is lower than Emerald Health Therapeutics Inc.'s recent average Revenue surge of 958.45%.

Looking into fourth quarter 2018 results within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Revenue growth. While Emerald Health Therapeutics Inc.' s Revenue doubling of 327.7% ranks overall at the positon no. 65 in the fourth quarter 2018.


EMHTF Revenue ( Y/Y Growth %) 2018
 2017 2016 2015
4th Quarter December 327.7 % - - -
3rd Quarter September 2844 % - - -
2nd Quarter June 1622.73 % - - -
1st Quarter March 553.33 % - - -
FY   926.28 % - - -

Financial Statements
Emerald Health Therapeutics's fourth quarter 2018 Revenue $ 3.72 millions EMHTF's Income Statement
Emerald Health Therapeutics's fourth quarter 2017 Revenue $ 0.87 millions Quarterly EMHTF's Income Statement


EMHTF Revenue (Quarter on Quarter Growth %)

 2018
 2017 2016 2015
4th Quarter December -49.44 % 248 % - -
3rd Quarter September 94.2 % 13.64 % - -
2nd Quarter June 93.37 % -26.67 % - -
1st Quarter March 125.29 % - - -
FY (Year on Year)   926.28 % - - -


Back to EMHTF Growth rate Comparisons >> Back to EMHTF Growth rate Comparisons >>


Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #18
Overall #65

Revenue Y/Y Growth Statistics
High Average Low
958.45 % 958.45 % 958.45 %
(Dec 31 2019)  
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #18
Overall #65
Revenue Y/Y Growth Statistics
High Average Low
958.45 % 958.45 % 958.45 %
(Dec 31 2019)  

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Emerald Health Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
253.53 % 71.93 % -49.44 %
(Dec 31 2018)  


EMHTF's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2018 Emerald Health Therapeutics Inc. disclosed fall in Revenue from the third quarter by -49.44% to $ 3.72 millions, from $ 7.36 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2018 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 257 other companies have achieved higher Revenue quarter on quarter growth. While Emerald Health Therapeutics's Revenue growth quarter on quarter, overall rank is 4395.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #258
Healthcare Sector #635
Overall #4395
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #258
Healthcare Sector #635
Overall #4395
Revenue Q/Q Growth Statistics
High Average Low
253.53 % 71.93 % -49.44 %
(Dec 31 2018)  


EMHTF's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2018 Emerald Health Therapeutics Inc. disclosed fall in Revenue from the third quarter by -49.44% to $ 3.72 millions, from $ 7.36 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2018 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 257 other companies have achieved higher Revenue quarter on quarter growth. While Emerald Health Therapeutics's Revenue growth quarter on quarter, overall rank is 4395.


Emerald Health Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2019)		 12 Months Ending
 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 17.11 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 958.45 % - - - -
Year on Year Revenue Growth Overall Ranking # 24 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 958.45 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 24 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 958.45% annual Revenue growth, Emerald Health Therapeutics Inc. would report a record annual Revenue surge if the fiscal year would end on Dec 31 2019.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 24.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 9
Overall # 24

Revenue TTM Y/Y Growth Statistics
High Average Low
958.45 %
 958.45 %
958.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 9
S&P 500 # 24
Cumulative Revenue growth Comment
With 958.45% annual Revenue growth, Emerald Health Therapeutics Inc. would report a record annual Revenue surge if the fiscal year would end on Dec 31 2019.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 24.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 9
Overall # 24

Revenue TTM Y/Y Growth Statistics
High Average Low
958.45 %
958.45 %
958.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 9
S&P 500 # 24




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EMHTF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2019
Pfenex Inc 553.69%$ 553.685 millions
Decoy Therapeutics Inc 536.97%$ 536.973 millions
Arcus Biosciences Inc 524.20%$ 524.200 millions
Allarity Therapeutics Inc 504.57%$ 504.568 millions
Bionexus Gene Lab Corp 464.35%$ 464.351 millions
Fresh Tracks Therapeutics Inc 439.52%$ 439.516 millions
Agenus Inc434.83%$ 434.832 millions
Acadia Healthcare Company Inc 428.74%$ 428.736 millions
Bicycle Therapeutics Plc399.62%$ 399.622 millions
Progenics Pharmaceuticals Inc367.14%$ 367.140 millions
Insmed Inc364.75%$ 364.748 millions
Dicerna Pharmaceuticals Inc 359.44%$ 359.442 millions
Ocular Therapeutix Inc 347.62%$ 347.619 millions
Emerald Health Therapeutics Inc.328.38%$ 328.378 millions
Cogent Biosciences Inc 301.79%$ 301.787 millions
Option Care Health Inc 292.65%$ 292.650 millions
Optinose Inc 266.56%$ 266.556 millions
Endonovo Therapeutics Inc 252.34%$ 252.339 millions
Palvella Therapeutics Inc 251.52%$ 251.516 millions
Taiwan Liposome Company Ltd 243.42%$ 243.418 millions
Alnylam Pharmaceuticals Inc 240.80%$ 240.803 millions
Immunogen inc 234.41%$ 234.407 millions
Telesis Bio Inc 229.10%$ 229.103 millions
Biotricity Inc 224.63%$ 224.634 millions
Cue Biopharma Inc 217.40%$ 217.398 millions
Avita Medical Inc 213.37%$ 213.365 millions
Therapeuticsmd Inc 212.48%$ 212.478 millions
Verastem Inc 198.93%$ 198.926 millions
Phasebio Pharmaceuticals Inc.197.28%$ 197.276 millions
Adma Biologics Inc 196.74%$ 196.740 millions


About Emerald Health Therapeutics Revenue Growth Rates (EMHTF), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.